Abstract Number: 1421 • ACR Convergence 2023
Domains Impacting Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors Receiving Guselkumab (COSMOS)
Background/Purpose: Sustained minimal disease activity (MDA) is achieved by a minority of patients (pts) receiving biologics for psoriatic arthritis (PsA). Pt-reported MDA domains are less…Abstract Number: 1981 • ACR Convergence 2023
The Association Between X-ray Progression and Clinical Outcomes in Patients with Hand Osteoarthritis with 5-year Follow-up
Background/Purpose: Hand osteoarthritis (HOA) is a heterogeneous disorder with two main subtypes, non-erosive and erosive. The progression of HOA is assessed by various radiographic scoring…Abstract Number: 2229 • ACR Convergence 2023
Individual Entheseal Points Have Differential Frequency of Involvement and Impact on Patient Reported Outcomes in Patients with Active Psoriatic Arthritis: Pooled Analysis of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies
Background/Purpose: In patients with mono/oligoarticular psoriatic arthritis (PsA), swelling or tenderness of specific joints can be associated with poorer patient-reported outcomes (PROs) and physician global…Abstract Number: 0229 • ACR Convergence 2023
Vegetable Consumption and Regular Exercise Are Associated with Better Quality of Life in Gout
Background/Purpose: Gout, which is a prevalent form of inflammatory arthritis, is generally considered to be more effectively managed through medication. Besides of maintaining medication, they…Abstract Number: 0386 • ACR Convergence 2023
Functional Disability and Disease Activity Are Affected by Social Determinants of Health in Patients with Rheumatoid Arthritis
Background/Purpose: The relationship between social determinants of health (SDH) (e.g. income, education, and employment status) and disease outcomes in the RA population is not well…Abstract Number: 0839 • ACR Convergence 2023
Efficacy and Safety of Nipocalimab in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA): The Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2a IRIS-RA Study
Background/Purpose: RA is a chronic inflammatory disease associated with autoantibodies. Despite the use of targeted therapies, up to half of patients fail to achieve remission…Abstract Number: 133 • 2023 Pediatric Rheumatology Symposium
An Interdisciplinary Team Approach to Implementation of a Social Determinants of Health Screener for Pediatric Rheumatology Patients
Background/Purpose: Adolescents with chronic disease often struggle with the transition from pediatric to adult healthcare leading to poor follow-up and negative health outcomes. Social determinants…Abstract Number: 0187 • ACR Convergence 2022
Patient-reported Outcomes and Quality of Life in Patients with Rheumatoid Arthritis Treated with GP2015: Final Results from a Real-world Study
Background/Purpose: COMPACT is a non-interventional study evaluating the persistence, effectiveness, safety and patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA), axial-spondyloarthritis or psoriatic arthritis…Abstract Number: 0243 • ACR Convergence 2022
Real World Evidence of Treatment Effectiveness and Unfavorable Clinical Events for Elderly-onset Early Rheumatoid Arthritis in Japan: Results from the IORRA Study
Background/Purpose: The number of elderly patients with rheumatoid arthritis (RA) has been constantly increasing. As of December 2021, 50.3% of the patients with RA who…Abstract Number: 0313 • ACR Convergence 2022
Olokizumab Improves Patient Reported Outcomes in Moderate to Severely Active Rheumatoid Arthritis Patients Inadequately Controlled by Methotrexate (MTX-IR): Results from the Phase III Randomized Controlled Trial
Background/Purpose: Olokizumab (OKZ) is an interleukin-6-inhibitor for treatment of Rheumatoid Arthritis (RA). In these analyses, we present patient reported outcomes (PROs) reported by MTX-IR patients…Abstract Number: 0314 • ACR Convergence 2022
Olokizumab Improved Patient Reported Outcomes in TNF Incomplete Responder (TNF-IR) Rheumatoid Arthritis Patients: Results from the Phase III Randomized Controlled Trial
Background/Purpose: Olokizumab (OKZ) is an interleukin-6-inhibitor for treatment of rheumatoid arthritis (RA). In these analyses we present patient reported outcomes (PROs) reported by TNF-IR patients…Abstract Number: 0437 • ACR Convergence 2022
Outcome Measures in Patients with Neurologic Involvement in ANCA-associated Vasculitis: Data from Multicenter Longitudinal Observational Study
Background/Purpose: Neurologic involvement (NI) in ANCA-associated vasculitis (AAV) is common, occurring in approximately one-third of patients, and leads to significant and often chronic functional limitations…Abstract Number: 0699 • ACR Convergence 2022
Effectiveness by Disease Severity in Patients with Psoriatic Arthritis Treated with Apremilast in the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Background/Purpose: Clinical trials of the efficacy and safety of apremilast have shown a significant therapeutic effect on disease activity across clinically diverse PsA patients. Given…Abstract Number: 0891 • ACR Convergence 2022
Rheumatoid Arthritis and the Rheumatic Disease Comorbidity Index (RDCI): Its Impact on Disease Activity
Background/Purpose: Comorbid conditions in the setting of rheumatoid arthritis (RA) play an important role in predicting disease activity and functional impairment (1). Application of a…Abstract Number: 1468 • ACR Convergence 2022
Apathy Measurement in a Cohort of Systemic Lupus Erythematosus
Background/Purpose: Up to 40% of patients with systemic lupus erythematosus (SLE) have measurable cognitive dysfunction on neuropsychiatric testing. Around 83% of patients are nonadherent with…
ACR Meeting Abstracts